春立医疗 (688236.SH) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	1.0B	1.0B	805.9M	1.2B	1.2B
Cost of Revenue	351.8M	355.1M	269.0M	332.6M	288.1M
Gross Profit	681.1M	690.6M	536.9M	875.9M	913.5M
Operating Expenses
R&D Expense	118.1M	118.5M	133.1M	157.4M	162.3M
SG&A Expense	—	—	—	—	—
General & Admin Expense	46.8M	52.3M	45.3M	44.5M	38.8M
Selling & Marketing Expense	191.2M	198.2M	240.2M	383.1M	391.5M
Other Expenses	—	—	—	—	—
Total Operating Expenses	359.2M	367.7M	409.3M	579.3M	585.8M
Cost and Expenses	711.0M	722.9M	678.2M	912.0M	873.9M
Operating Income (EBIT)	305.8M	302.2M	130.7M	306.0M	328.9M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	305.2M	301.7M	131.6M	305.9M	336.9M
Income Tax Expense	29.0M	29.1M	6.9M	28.1M	29.2M
Bottom Line
Net Income	276.2M	272.5M	125.0M	277.8M	307.7M
Earnings from Cont. Ops	276.3M	272.6M	124.7M	277.8M	307.7M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	276.2M	272.5M	125.0M	277.8M	307.7M
Per Share
Basic EPS	CN¥0.72	CN¥0.71	CN¥0.33	CN¥0.72	CN¥0.80
Diluted EPS	CN¥0.72	CN¥0.71	CN¥0.33	CN¥0.72	CN¥0.80
Revenue Per Share	CN¥2.68	CN¥2.72	CN¥2.13	CN¥3.13	CN¥3.12
Shares
Basic Shares Outstanding	385.7M	383.9M	378.8M	385.9M	384.6M
Diluted Shares Outstanding	385.7M	383.9M	378.8M	385.9M	384.6M
Profitability Metrics
EBITDA	—	341.8M	167.6M	339.2M	357.2M
D&A	—	39.6M	36.9M	33.3M	28.3M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026